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Developing a New Version of the SF-6D Health
State Classification System From the SF-36v2:
SF-6Dv2
John E. Brazier, PhD,* Brendan J. Mulhern, MRes,*† Jakob B. Bjorner, PhD,*‡§
Barbara Gandek, PhD,∥¶✠ Donna Rowen, PhD,* Jordi Alonso, PhD,#**††
Gemma Vilagut, PhD,#†† John E. Ware, PhD,∥¶
and on behalf of the SF-6Dv2 International Project Group
Objective: The objective of this study was to develop the classification
system for version of the SF-6D (SF-6Dv2) from the SF-36v2.
SF-6Dv2 is an improved version of SF-6D, one of the most widely used
generic measures of health for the calculation of quality-adjusted life years.
Study Design and Setting: A 3-step process was undertaken to gen-
erate a new classification system: (1) factor analysis to establish di-
mensionality; (2) Rasch analysis to understand item performance; and (3)
tests of differential item function. To evaluate robustness, Rasch analyses
were performed in multiple subsets of 2 large cross-sectional datasets
from recently discharged hospital patients and online patient samples.
Results: On the basis of factor analysis, other psychometric evidence,
cross-cultural considerations, and amenability to valuation, the 6-di-
mension classification used in SF-6D was maintained. SF-6Dv2 resulted
in the following modifications to SF-6D: a simpler classification of
physical function with clearer separation between levels; a more detailed
5-level description of role limitations; using negative wording to de-
scribe vitality; and using pain severity rather than pain interference.
Conclusions: The SF-6Dv2 classification system describes more
distinct levels of health than SF-6D, changes the descriptions used
for a number of dimensions and provides clearer wording for health
state valuation. The second stage of the study has developed a utility
value set using discrete choice methods so that the measure can be
used in health technology assessment. Further work should inves-
tigate the psychometric characteristics of the new instrument.
Key Words: SF-36, SF-6D, utilities, quality adjusted life year,
Rasch analysis
(Med Care 2020;58: 557–565)
In the economic evaluation of health interventions, the qualityadjusted life year (QALY) can be used to measure outcomes.
The QALY combines length and quality of life into a single
figure. The quality aspect (or utility value) is anchored on a 0
(dead) to 1 (full health) scale, and can be derived from generic
preference-based measures (GPBM) of health.
One such GPBM is the SF-6D (hereon SF-6Dv1)1,2;
which was developed from version 1 of the SF-36.3 The SF-
6Dv1 describes health on 6 dimensions [physical functioning
(PF), role limitations (RL), social functioning (SF), pain,
mental health (MH), and vitality (VT)], 4–6 severity levels,
therefore describing 18,000 health states (Fig. 1). The United
Kingdom value set was developed using the standard gamble
elicitation technique and ranges from 0.29 to 1.1
The SF-6Dv1 has become one of the most widely used
GPBMs in economic evaluation.4 Country specific value sets
have been developed5–12 and it is accepted by international
reimbursement agencies.13 SF-6Dv1 has been shown to have
psychometric validity and responsiveness to change across
common mental health14,15 and physical health conditions.16,17
The SF-6Dv1 has not been without criticism. The severity
ordering of the PF dimension (between “a lot” of limitations with
moderate activities and “a little” limitation with bathing and
dressing) is unclear.1 The VT dimension is positively framed in
comparison to the other dimensions. This may cause respondents
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confusion during valuation. The role dimension has limited
sensitivity as it was based on combinations of 2 role items each
with only 2 response levels. This resulted in claims of a “floor”
effect, with many patients answering at the lowest severity
level.18,19 The SF-6Dv1 was also developed using SF-36v1, and
there is the opportunity to revisit the classification system using
the improved SF-36v2.20,21
Moreover, there were additional concerns raised with
regard to the valuation task used to derive the SF-6Dv1 value
set. On one hand, the valuation technique used for SF-6Dv1,
the standard gamble is a cognitively difficult technique, and
given the iterative nature of the risk trade off concerns have
been raised about respondent understanding of probability
and risk aversion, which may lead to higher health state
values. Furthermore, the valuation task involved a 2 stage
chained process with states being valued against full health
and the worst state, then the worst state being valued against
full health and dead, which generates higher values by dou-
bling the impact of risk aversion. Valuation using ranking,22
Bayesian methods23 and discrete choice experiments, in-
cluding duration (DCETTO),
13 have all produced lower values
for the more severe states resulting in a wider utility range.
We therefore aimed to address these concerns by de-
veloping a new version of the SF-6Dv1 (SF-6Dv2). This
includes 2 objectives: (1) to develop a “new” health state
classification system from the SF-36v2 using psychometric
evidence; and (2) to derive a value set that can be used in the
calculation of QALYs. This paper reports on the first ob-
jective. The second objective is reported elsewhere.24
METHODS
Overview
We built on SF-6Dv1 and developed a new health state
classification system that reflects the content of the SF-36, and
produced health states amenable to valuation. To do this we used
a 3-step process. Step 1 evaluated the dimensionality of the
SF-36 for use in the classification system; Step 2 involved item
elimination and selection; and Step 3 involved further analyses of
the robustness of the Step 2 results across different data subsets.
The dimension formation and item selection criteria used Factor
and Rasch analyses, and other criteria such as cross-cultural
relevance. Contrary to SF-6Dv1, item selection was not restricted
to those also included in SF-12. This iterative methodological
process was developed by a number of the authors, and has been
applied widely to generate classification systems from existing
profile measures.25–27
The SF-36
SF-363,28 is a measure of health that has been widely
used and validated. It has 36 items across 8 dimensions: PF,
role limitations due to physical health (RP), bodily pain (BP),
general health (GH), VT, SF, role limitations due to emo-
tional problems (RE), and MH. The SF-36v2 was used to
develop SF-6Dv2. The SF-36v2 is an improved version of the
SF-36v1. Changes included increasing the RP and RE item
response levels from 2 to 5 to improve sensitivity, and sim-
plifying the MH and VT items by reducing the levels from 6
to 5. Wording changes were also made.20,21
Data
Data used for this study were sourced from the 2
samples described below.
Health Outcome Data Repository Dataset29
Health Outcome Data Repository Dataset (HODaR) is a
survey of recently discharged hospital inpatients and out-
patients in the United Kingdom. The data included 49,029
full completers of the SF-36v2 between August 2002 and
November 2008. The SF-36v2 was administered postally ∼6
weeks after discharge, with other information linked from
hospital records.
Multi Instrument Comparison Study30
Multi Instrument Comparison (MIC) is a survey of
respondents self-reporting a range of health conditions, and a
“healthy public” sample. The data used were from 5,331 re-
spondents who fully completed the SF-36v2 online in the
United Kingdom (n= 1358), Canada (n= 1335), Australia
(n= 1171), and the United States (n= 1467).
The 2 samples covered a wide range of conditions and
included a large proportion reporting comorbid health problems.
Table 1 reports demographics and Appendix 1 (Supplemental
Digital Content 1, http://links.lww.com/MLR/C7) provides
detailed descriptions of the datasets.
Step 1—Dimensionality Assessment
We determined the dimensions to include in the clas-
sification system by evaluating the dimensionality of the SF-
36v2 using exploratory (EFA) and confirmatory (CFA) factor
analysis. This was done considering the SF-6Dv1 6-di-
mension structure, and we looked for evidence supporting the
inclusion of more or fewer dimensions. Past work assessing
SF-36 dimensionality was also considered.31 This included
research both supporting the hypothesized 8 factor
structure,32–34 and suggesting that the direction of the item
response wording may impact dimensionality assessment due
to response set patterns.35,36 Work from Asia suggesting that
the physical and emotional role dimensions load as one factor
was also considered.37
The 5 GH items, and the health transition question,
were not included as these are not relevant for a classification
system assessing specific constructs of health. Factor analysis
was conducted using Stata 15.38
The decision process used to select the dimensionality
was also informed by face validity, conceptual coverage and
cross-cultural issues. This was supported by input from the
SF-6Dv2 international project team (including experts from
17 countries).
Exploratory Factor Analysis
EFA was used to identify patterns of loadings and ex-
amine dimensionality without assuming a prior structure by
assessing the degree to which the item correlations can be
explained by a number of factors. The number of factors to
extract can be decided using eigenvalue analysis, or set by the
analyst with consideration of the variance explained. We
assessed the Kaiser-Meyer-Olkin measure of sample
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adequacy, which ranges between 0 and 1, where smaller
values indicate that EFA may be inappropriate.
We extracted models with 2 to 9 factors (including the
model suggested by the criteria of accepting factors with ei-
genvalues > 1) on the full samples from both datasets. To
ensure reliability, models were also tested on randomly selected
subsamples. For each model we assessed the adequacy of the
conceptual structures for developing a classification system.
Models were developed using oblique promax rotation,
which assumes dimension correlations. We used polychoric
correlations due to the ordinal responses. Items loading on a
dimension with a correlation of <0.4, or cross-loading be-
tween dimensions within 0.2, were identified as demonstrat-
ing poor fit, but were not excluded from the model given the
aim to develop a conceptually relevant classification system.
This was in line with other studies developing classification
systems.25–27
Confirmatory Factor Analysis
CFA39 assesses the fit of hypothesized factor structures
by comparing the observed item correlation or covariance
matrix with the expected matrix from the specified model.
Analysis was conducted on the full sample from the HODaR
and MIC datasets separately, with subsample analyses also
performed. We used a range of statistics to assess model fit
and guide dimensionality development. These included the
root mean square error of approximation (RMSEA), and the
standardized root mean square residual (SRMR) estimates of
fit, where a value of. 08 or less indicated reasonable model fit
and 0.05 or less indicated good fit.40,41 Two indices that take
into account model fit and complexity, the comparative fit
index (CFI)42 and the Tucker and Lewis43 Index (TLI), were
also used. These range from 0 to 1, with values above 0.90
and 0.95 considered reasonable and excellent fit, respectively.
These measures have been previously used to assess SF-12
and SF-36.44,45
The fit of 8 models was tested: a 7 factor model aligning
with the SF-36 (PF, RP, RE, SF, BP, MH, VT for HODaR and
MIC; models 1 and 2), the models produced using the selection
criterion of eigenvalues >1 (models 3 and 4), and the best
conceptually fitting models from EFA (models 5 and 6). CFA
was also conducted on the model used for the classification
system (models 7 and 8).
Step 2 and 3—Classification System
Development
Rasch analysis46 models the relationship between cat-
egorical item responses in a multi item scale and a continuous
latent scale which measures an assumed underlying unidi-
mensional construct (in this case the aspect of health mea-
sured). As Rasch models assume unidimensionality, a
separate model was evaluated for each dimension. The
probability of a response to each level of each item was used
to assess the severity of the item against the underlying latent
construct. This allowed a range of item performance in-
dicators to be assessed. Rasch analysis was conducted using
RUMM2030.47
We evaluated Rasch fit statistics which assess the di-
vergence between expected and observed responses for both
respondents (person-fit residuals) and items (item-fit re-
siduals). Items with a fit residual outside the standard cutoff
of ± 2.5 were considered for exclusion.
The Rasch model was also used to assess systematic
differences in item response patterns for different subgroups
of respondents [known as differential item functioning
(DIF)]. DIF was detected using a 2-way analysis of variance
assessment of the standardized residuals of the responses,
where one factor was the class intervals representing severity
across the latent trait scale and the other factor was the
demographic subgroup.48 We tested for DIF based on age,
sex and whether a health condition was reported. There are 2
types of DIF, uniform and nonuniform. Uniform DIF occurs
when a subgroup consistently differs in their responses to an
item conditional on the trait estimate. Presence of uniform
DIF was indicated by a significant main effect for estimates
for each item across demographic groups. Nonuniform DIF
occurs when the association between item responses and
TABLE 1. Summary of HODaR and MIC Datasets
HODaR MIC
Sample size 49,029 5331
Country [n (%)]
United Kingdom 49,029 (100) 1358 (25.5)
Canada NA 1335 (25.0)
Australia NA 1171 (22.0)
United States NA 1467 (27.5)
Age category (y)
18–24 2082 (4.2) 324 (6.1)
25–34 3728 (7.6) 651 (12.2)
35–44 5560 (11.3) 726 (13.6)
45–54 7586 (15.5) 1068 (20.0)
55–64 10,568 (21.6) 1400 (26.3)
65+ 19,505 (39.8) 1162 (21.8)
Female [n (%)] 24,563 (50.1) 2281 (55.9)
Education above school leaving age NM 3467 (65.0)
Married/partner NM 3397 (63.7)
Health status [n (%)]
Good-excellent 28,198 (57.5) 3330 (62.5)
Fair-poor 20,831 (42.5) 2001 (37.5)
Condition [n (%)]
Healthy population NM 947 (17.8)
Asthma NM 579 (10.9)
Cancer/any tumor 7202 (14.7) 577 (10.8)
Depression NM 617 (11.6)
Diabetes 4205 (8.6) 641 (12.0)
Hearing problems NM 601 (11.3)
Arthritis NM 640 (12.0)
Heart disease 4129 (8.4) 706 (13.2)
COPD 5518 (11.3) NM
Peripheral/cerebrovascular disease 2696 (5.5) NM
Dementia 34 (0.1) NM
Liver disease 149 (0.3) NM
Connective tissue disease 447 (0.9) NM
Renal disease 895 (1.8) NM
Hemiplegia 310 (0.6) NM
Ulcer disease 922 (1.9) NM
HIV 46 (0.1) NM
Report comorbidity on Charlson index 19,528 (39.8) NM
SF-6D index
Mean (SD) 0.66 (0.15) 0.70 (0.14)
Range 0.30–1 0.30–1
COPD indicates chronic obstructive pulmonary disease; HIV, human im-
munodeficiency viruses; HODaR, Health Outcomes Data Repository dataset; MIC,
Multi Instrument Comparison Study dataset; NA, not applicable; NM, not measured.
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group is not constant across the severity range. In the analysis
this was indicated by a significant interaction effect between
the subgroup and the severity range of the latent trait. A
Bonferroni adjustment was applied to the significance esti-
mates.
We additionally assessed items for inclusion in the
classification system considering a range of criteria such as
item severity range coverage, where a large distance from the
lowest to the highest item response threshold indicates that an
item provides measurement precision over a wider range.
Other criteria included avoiding complex item combi-
nations and descriptions which may be difficult to understand
and subsequently value. The face validity of the dimension
wording was also evaluated.
Assessing the Robustness of the Results
To enhance robustness, Rasch and DIF analyses were
conducted on 9 subsamples of combined HODaR and MIC
data randomly selected for a sample of ∼500 (a recommended
sample size for Rasch analysis).49 The subsamples did not
significantly differ in terms of age, sex or health status. Each
of the items was given an overall score (of 9) indicating the
number of samples that the item performed well on. An item
was considered for inclusion if it performed well on at least 5
of the 9 subsamples. However, in some cases items with lower
performance remained for selection due to other criteria.
RESULTS
Step 1—Dimensionality Assessment
Exploratory Factor Analysis
Appendix 2 (Supplemental Digital Content 1, http://
links.lww.com/MLR/C7) includes the EFA models with be-
tween 2 and 9 factors estimated on both datasets. The EFA
models with between 2 and 6 dimensions combined a number
of existing SF-36 dimensions within the factor structure, so
were not suitable for developing a classification system.
Models with 8 and 9 factors included redundant factors that
were difficult to interpret and define.
The model including 7 factors was most in line with the
original SF-36, and explained 75.1% (HODaR) and 67.8%
(MIC) of the variance. The Kaiser-Meyer-Olkin of the models
was high (> 0.95) indicating that sample was adequate for
factor analysis. Across the HODaR and MIC models, there
were 5 factors consistent across the 2 datasets and 2 factors
that included similar items with minor variation. Each factor
is described below:
 Factor 1 (consistent): All 10 items from the PF dimension.
 Factor 2 (minor variation): Both models included the 4 RP
items, and the HODaR model included the 2 SF items.
 Factor 3 (consistent): All 3 RE items.
 Factor 4 (consistent): 2 BP items.
 Factor 5 (minor variation): The HODaR model included
the 5 MH items. The MIC model included the 3 negatively
framed MH items.
 Factor 6 (consistent): The 4 positively framed items from
the MH and VT. The 2 MH items cross-loaded with factor
5 in the HODaR data.
 Factor 7 (consistent): The 2 negatively framed VT items.
The SF dimension did not uniquely load on a single
factor in either model, and failed to load at a level of 0.4 in
the MIC model. The positively framed VT items loaded with
the 2 positive MH items in MIC. The MH items loaded on
one factor in the HODaR model, and on separate positive and
negative factors in MIC.
Confirmatory Factor Analysis
Table 2 reports the CFA model fit. The worst performing
models were those based on the factor structures produced using
eigenvalue criteria (models 3 and 4). The models most consistent
with the standard SF-36 structure (1 and 2) had CFI and TLI
scores above the cutoff, but were below the models from the EFA
[which would be expected given these are based on the same data
samples (models 5 and 6)]. Models 1 and 2 performed better on
the SRMR criteria in comparison to models 5 and 6, but lower
RMSEA values were observed.
Decisions Regarding Dimensionality
PF explained the most variance and was retained. The role
physical and role emotional dimensions were combined to cre-
ate a single role dimension (RL) for 3 reasons. First, there is
evidence from some Asian cultures that role limitations due to
emotional problems is not recognized and so should not be
separated out.37 Second, CFA modeling (Table 4, models 7 and
8) suggested that the correlation coefficients for the combined
role dimension were acceptable. Third, including separate role
physical and role emotional dimensions could complicate the
valuation process. Although social limitations were correlated
with RLs, the importance of general social activities with friends
and family, and the likely impact of health interventions on
social aspects, led to retaining this as an individual dimension
assessing general SF. The 2 pain items formed a strong factor in
both samples. These first 4 dimensions were negatively worded,
and it was decided to ensure MH and VT were consistent with
this. There was evidence from MIC that the positively worded
items for MH overlap with VT. For MH the negatively worded
items were part of the MH factor in HoDAR and formed a
TABLE 2. Confirmatory Factor Analysis Model Fit Statistics
Model Number
1 2 3 4 5 6 7 8
RMSEA 0.084 0.088 0.152 0.147 0.080 0.079 0.085 0.078
SRMR 0.041 0.043 0.068 0.077 0.048 0.048 0.036 0.043
CFI 0.917 0.901 0.816 0.806 0.926 0.923 0.934 0.932
TLI 0.905 0.886 0.792 0.781 0.914 0.911 0.923 0.920
N 49,029 5331 49,029 5331 49,029 5331 49,029 5331
Models 1 and 2: 7 factor models aligning with the SF-36 (PF, RP, RE, SF, BP, MH,
VT, excluding GH) for HODaR and MIC, respectively.
Models 3 and 4: 3 factor models produced using the factor selection criterion of
eigenvalues > 1 for the HODaR and MIC.
Models 5 and 6: Best conceptually fitting models identified from the EFA for the
HODaR and MIC data with 7 dimensions.
Models 7 and 8: The final 6 factor model used for health state classification system
run on the HODaR and MIC data.
BP indicates bodily pain; CFI, Comparative Fit Index; GH, general health; HODaR,
Health Outcome Data Repository Dataset; MH, mental health; MIC, Multi Instrument
Comparison; PF, physical functioning; RMSEA, root mean square error of approx-
imation; SF, social functioning; SRMR, standardized root mean square residual; TLI,
Tucker-Lewis Index; VT, vitality.
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single factor in MIC. The negatively framed items were retained
as a single MH dimension. The negatively framed VT items
formed their own factor in both datasets, in line with earlier
work,36 so were used as a simplified description of VT.
This 6 dimensional structure was in line with that used
for SF-6Dv1. Table 2 reports the CFA model fit results based
on the selected factor structure (models 7 and 8). These
models had acceptable CFI and TLI scores. Model 7 had the
lowest overall SRMR and model 8 had the lowest RMSEA.
Table 3 reports the factor loadings from the CFA models for
the final 6 factor model, and shows that all coefficients were
above the minimum level. This provides support for retaining
the 6 dimensional structure as the basis for the classification
system.
Steps 2 and 3—Item Selection and Health State
Classification System Development
The process for selecting items for each dimension is
outlined below. Table 4 displays the results including the
overall score for the number of times the item performed well
of 9 subsamples, and scores regarding the times DIF or poor
fit was exhibited. Appendix 3 (Supplemental Digital Content
1, http://links.lww.com/MLR/C7) includes an item-by-item
summary of their performance, including the stage at which
the item was excluded, and which were retained.
Physical Functioning
Of the 10 items from the SF-36 PF scale, there was
evidence of misfit for 4 items. Two items displayed DIF
by sex.
Of the remaining 4 items, the vigorous activity and
bathing and dressing limitation items were selected to ensure
the dimension was sensitive to the less severe (mean latent
scale coverage 1.63 to 3.78) and more severe (coverage −3.71
to −1.42) range, respectively. As these items did not overlap
in values on the latent scale, the item assessing moderate
activity limitations was chosen to cover the mid-range of the
severity scale (mean range −0.88 to 1.64). This item did
demonstrate misfit in a number of the analyses. However,
retaining this item in the classification system increased
sensitivity across the severity range.
Role Limitations
Across the role physical and role emotional dimensions,
all 7 items had good Rasch statistics on the majority of
analyses and covered a similar severity range. A key criterion
was face validity, and the physical and emotional role di-
mensions were combined to tackle cross-cultural factors
linked to evidence that RL due to emotional problems is not
recognized in some Asian countries. Therefore, it was de-
cided to use items assessing the same concept across
both physical and emotional RLs. This resulted in the item
“Accomplished less than you would like” being used for both
but with attribution to either physical health or emotional
problems.
Social Functioning
Both items performed well, and covered a similar se-
verity range, with the average position centrally located on
the logit scale (0.01 and −0.01). Because of this, and for
consistency with SF-6Dv1, it was decided to retain the social
activity limitation frequency item.
Pain
There was more evidence of misfit for pain interference
(7/9 samples) compared to pain severity (4/9 samples). The
pain severity item covered a wider range, particularly at
milder severity. Furthermore, it avoided reference to inter-
ference with work and correlated less with the PF, RP, and
RE dimensions. For these reasons pain severity was selected.
Mental Health
The item “down in the dumps” displayed item misfit.
The negatively worded items for assessing frequency of being
“very nervous” and “down and depressed” remained for se-
lection following the Rasch analysis and they were combined
as one dimension within the classification system.
TABLE 3. Confirmatory Factor Analysis Loadings for 6
Factor Model
CFA Loading*
Dimension/Item HODAR MIC
Physical functioning
Q3. Limited vigorous activities 0.665 0.677
Q4. Limited moderate activities 0.845 0.837
Q5. Limited lifting or carrying groceries 0.832 0.804
Q6. Limited climbing several flights of stairs 0.860 0.842
Q7. Limited climbing one flight of stairs 0.854 0.853
Q8. Limited bending kneeling or stooping 0.794 0.765
Q9. Limited walking > 1 mile 0.876 0.868
Q10. Limited walking several hundred yards 0.896 0.878
Q11. Limited walking 100 yards 0.834 0.813
Q12. Limited bathing or dressing 0.711 0.609
Role physical
Q13. Cut down time spent on work/other activities 0.923 0.888
Q14. Accomplished less than you would like 0.945 0.908
Q15. Limited in the kind of work/other activities 0.952 0.937
Q16. Difficulty performing work or other activities 0.956 0.944
Role emotional
Q17. Cut down time spent on work/other activities 0.637 0.667
Q18. Accomplished less than you would like 0.644 0.643
Q19. Did work or other activities less carefully 0.631 0.645
Social functioning
Q20. Physical/emotional health interfere with social
activities (extent)
0.903 0.859
Q32. Physical/emotional health interfere social
activities (frequency)
0.903 0.880
Pain
Q21. Severity of bodily pain 0.784 0.831
Q22. Extent pain interfered with normal work 0.981 0.959
Mental health—negatively worded items
Q24. Very nervous 0.723 0.719
Q25. Down in the dumps 0.878 0.871
Q28. Downhearted and depressed 0.874 0.895
Vitality—negatively worded items
Q29. Feel worn out 0.890 0.908
Q31. Feel tired 0.835 0.834
*The loading values in the table are taken from the CFA model testing the final 6
factor structure used to select items for the classification system.
CFA indicates confirmatory factor analysis; HODaR, Health Outcome Data
Repository Dataset; MIC, Multi Instrument Comparison.
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TABLE 4. Rasch Analysis, and Summary of Chosen Dimension Structure
Mean Item Level Performance
Dimension/Item
Overall
Score* Range† Location‡
Fit
Residual§ P DIF‖ Item Misfit¶ Selected
Physical functioning
Q3. Limited vigorous activities 8/9 1.63–3.78 2.71 0.23 0.28 Sex (1 sample) No misfit √
Q4. Limited moderate activities 3/9 −0.88 to 1.64 0.38 −1.31 0.17 No DIF evidence Misfit (6 samples) √
Q5. Limited lifting or carrying
groceries
2/9 −1.78 to 1.29 −0.25 −1.05 0.10 Sex (6 samples) Misfit (1 sample) X
Q6. Limited climbing several
flights of stairs
1/9 −0.50 to 2.30 0.90 −2.06 0.17 Sex (3 samples) Misfit (5 samples) X
Q7. Limited climbing one flight
of stairs
3/9 −2.46 to 0.33 −1.07 −1.92 0.10 No DIF evidence Misfit (6 samples) X
Q8. Limited bending kneeling or
stooping
9/9 −1.02 to 1.95 0.47 −0.04 0.15 No DIF evidence No misfit X
Q9. Limited walking > 1 mile 2/9 0.087–1.43 0.76 −2.34 0.04 Age (1 sample) Misfit (6 samples) X
Q10. Limited walking several
hundred yards
0/9 NA# NA NA NA No DIF evidence Misfit (9 samples) X
Q11. Limited walking 100 yards 6/9 −2.32 to −0.55 −1.44 −0.99 0.18 No DIF evidence Misfit (3 samples) X
Q12. Limited bathing or dressing 8/9 −3.71 to −1.42 −2.56 0.19 0.22 Age (1 sample) No misfit √
Role physical
Q13. Cut down time spent on
work/other activities
8/9 −3.34 to 2.46 −0.53 1.38 0.28 No DIF evidence Misfit (1 sample) X
Q14. Accomplished less than you
would like
9/9 −3.16 to 3.87 0.31 0.28 0.30 No DIF evidence No misfit √
Q15. Limited in the kind of
work/other activities
7/9 −2.84 to 3.11 0.10 −1.44 0.34 No DIF evidence Misfit (2 samples) X
Q16. Difficulty performing work or
other activities
9/9 −3.04 to 3.07 0.08 −0.96 0.39 No DIF evidence No misfit X
Role emotional
Q17. Cut down time spent on
work/other activities
9/9 −3.44 to 2.15 −0.20 −0.63 0.41 No DIF evidence No misfit X
Q18. Accomplished less than you
would like
7/9 −3.33 to 4.25 0.59 −0.90 0.09 Age (1 sample) Misfit (1 sample) √
Q19. Did work or other activities less
carefully
9/9 −3.58 to 2.75 0.34 1.07 0.31 No DIF evidence No misfit X
Social functioning
Q20. Physical/emotional health
interfere with social activities
(extent)
9/9 −2.88 to 2.75 0.01 0.48 0.30 No DIF evidence No misfit X
Q32. Physical/emotional health
interfere social activities
(frequency)
9/9 −2.81 to 2.51 −0.01 0.61 0.23 No DIF evidence No misfit √
Pain
Q21. Severity of bodily pain 5/9 −4.74 to 4.70 0.29 −0.51 0.13 No DIF evidence Misfit (4 samples) √
Q22. Extent pain interfered with
normal work
1/9 −2.20 to 2.33 −0.04 0.58 0.19 Sex (1 sample) Misfit (7 samples) X
Mental health—negatively worded items
Q24. Very nervous 6/9 −2.25 to 2.17 −0.16 1.05 0.24 No DIF evidence Misfit (3 samples) √
Q25. Down in the dumps 3/9 −3.11 to 2.18 −0.30 −0.36 0.08 No DIF evidence Misfit (6 samples) X
Q28. Downhearted and depressed 9/9 −1.78 to 2.56 0.21 0.19 0.22 No DIF evidence No misfit √
Vitality—negatively worded items
Q29. Feel worn out 8/9 −3.56 to 1.50 −0.88 0.44 0.12 No DIF evidence Misfit (1 sample) √
Q31. Feel tired 7/9 −2.75 to 3.33 0.08 −0.07 0.34 Sex (1 sample) Misfit (1 sample) X
*Number of the 9 Rasch analyses the item was valid for across each of the criteria (high scores better).
†Range on the latent scale.
‡Mean location parameter.
§Fit item-fit residual.
‖DIF (sample number is the number of sample the item exhibited DIF on across the 9 tested).
¶Number of times that particular item did not fit the Rasch model across the 9 samples and so was removed from the Rasch model.
#Results not available as the items was excluded as did not perform well on any of the 9 analyses.
X indicates item excluded from classification system; √, item included in classification system; DIF, differential item function; NA, not applicable.
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Vitality
Both the negatively framed VT items performed well.
The item assessing being “worn out” was selected over the
more general and less severe “tired” item.
SF-6Dv2 Classification System
The SF-6Dv2 classification system is displayed in
Figure 1, with SF-6Dv1 for comparison. The figure shows the
differences in the items selected, and the simplification of the
dimension level wording to support valuation. This was done
through an iterative process, led by authors J.E.B., B.J.M.,
and D.R., of adapting the item content and item level wording
into single sentences reflecting the original meaning of the
item. The process involved review and revision of potential
changes by the other authors and the international SF-6Dv2
team. Appendix 4 (Supplemental Digital Content 1, http://
links.lww.com/MLR/C7) demonstrates how the selected SF-
36v2 items were converted into the SF-6Dv2 classification
system. In constructing the classification, the team was aware
that the initial valuation will use DCETTO and this requires
respondents to compare states varying in content. The sim-
plification in wording was achieved by providing instructions
at the beginning of the task that the descriptions are because
of health.
The key changes in comparison to SF-6Dv1, are:
 PF uses the same items but reduces the levels from 6 to 5
to avoid ambiguity in level ordering by removing “Limited
a little in bathing and dressing”.
 RL descriptions are simplified by using the same item to
represent the 2 constituent dimensions. The increase to 5
levels takes advantage of the greater sensitivity of SF-36v2.
 SF is the same as for SF-6Dv1, with simplified level
descriptions.
 Pain has changed from interference to severity to increase
sensitivity to changes in pain intensity.
 MH includes both depression and anxiety focused items in
line with SF-6Dv1.
 VT has changed from positively worded “energy” to
negatively worded “worn out.”
CONCLUSIONS
In this study we have developed a new version of the
SF-6D classification system (SF-6Dv2) informed by
psychometric results and considering previous work testing
FIGURE 1. SF-6D health state classification system comparison.
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the limitations of SF-6Dv1. This process means that the SF-
6Dv2 should overcome many of the published criticisms of
SF-6Dv1 but maintain similarities. This is because we have
used the same dimension structure and retained much of the
descriptive content, whilst simplifying wording to support
valuation using DCETTO. We also involved international
experts to ensure cultural issues were considered. Some ex-
ploratory comparisons of the SF-6Dv1 and SF-6Dv2 using
the preferred value sets are reported elsewhere.24
There are improvements between versions to stand-
ardize the direction of the wording (VT), simplify the word-
ing (RL), remove inconsistencies (PF) and move towards the
measurement of pain severity (PA). Standardizing the direc-
tion of the wording has been shown to increase the psycho-
metric validity of tests.50 Item level changes will impact on
the ability to measure change in health status over time.
This study has a number of limitations and areas for
future work. First, we used datasets that were restricted to
westernized majority English speaking countries. To over-
come this the international expert group included researchers
involved in the original development and translation of SF-
36. This was influential in the decision to combine the role
dimensions. DIF analysis based on a wider range of demo-
graphics (such as language, education and country of resi-
dence) was not possible as we were restricted to the data
collected in the HODaR and MIC studies. In contrast to the
development of SF-6Dv1, we did not restrict the item se-
lection to those included in SF-12. SF-6Dv2 values will be
estimated from SF-12 using mapping algorithms in line with
methods used elsewhere.51
Further work is required to psychometrically test SF-6Dv2
in comparison to SF-6Dv1, particularly the responsiveness of
items to change. This will allow for further understanding of the
new classification system to support widespread use of the in-
strument. A key comparison is with the EQ-5D-5L.52,53 There
are important differences between the SF-6Dv2 and EQ-5D-5L
descriptive systems that will result in different psychometric
indicators. Comparisons in patient datasets will help understand
the relationship between the measures, and inform the use of
each in health technology assessment.
In conclusion, we have developed a simplified version
of the SF-6D classification system considering many of the
criticisms of SF-6Dv1. We have used updated psychometric
methods that allow insight into the choices made during the
development of SF-6Dv1. This led to the same dimension
structure, but with improvements. The classification system
will be valued internationally using valuation methods based
on DCE. The United Kingdom valuation is reported in a
companion paper,24 and subsequent international value sets
can be tested for use in the estimation of QALYs for the
economic evaluation of health interventions.
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